CMS-1773-P will establish a budget-neutral payment policy to smooth year-to-year changes in the hospice wage index; President Joe Biden pushes for $22 billion in COVID-19 funding from Congress; an FDA advisory panel said there is not enough evidence supporting the efficacy of the amyotrophic lateral sclerosis (ALS) treatment AMX0035.
CMS proposed a new rule Wednesday that would provide routine adjustments to hospice-based payments and the aggregate cap amount for the 2023 fiscal year, according to a CMS news release. The rule, CMS-1773-P, will establish a permanent, budget-neutral payment policy to smooth year-to-year changes in the hospice wage index, including a permanent cap on negative wage indexes greater than 5%, and make these updates based on existing statutory and regulatory requirements. Additionally, CMS-1773-P gives an update on HOPE, a patient assessment tool that would contribute to a patient’s plan of care.
As part of his announcement of COVID.gov, President Joe Biden also pushed for more COVID-19 funding from Congress, The Washington Post reported. In his appeal for at least $22 billion, Biden argued that the United States cannot wait until another wave of the virus to fight for more funding. This news comes after the FDA approval of a second COVID-19 booster for older adults, although officials said there is not enough funding to place advance orders to supply these additional doses for all older Americans unless Congress approves the funding request.
An FDA advisory panel said there is not enough evidence supporting the efficacy of the new amyotrophic lateral sclerosis (ALS) treatment AMX0035, which was developed by Amylyx Pharmaceuticals, The New York Times reported. The panel voted 6 to 4 that currently available scientific data collected from a small, mid-stage study on the 2-drug combination was insufficient to demonstrate that it could slow the progression of ALS. Still, the FDA will decide in the coming months whether to approve the ALS drug.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Study Highlights Disparities in Access to In-Network Mental Health Care vs Medical Care
April 17th 2024While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.
Read More